125 filings
Page 5 of 7
6-K
akhi0vok2fuamrb5k2h
26 Sep 19
Current report (foreign)
12:31pm
6-K
y5l2x6serx0w3
13 Sep 19
Current report (foreign)
1:24pm
6-K
gb42autoeu 7re
13 Sep 19
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
12:02pm
6-K
r687qxxx
30 Aug 19
Current report (foreign)
8:28am
6-K
km6epvr71kyg0fz
22 Aug 19
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
6:05am
6-K
tdkkw 3i1it
21 Aug 19
Capital Increase in Genmab as a Result of Employee Warrant Exercise
1:01pm
6-K
byyux2r51
14 Aug 19
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
12:00am
6-K
dgj5o4oi340 xqgqw7
23 Jul 19
Current report (foreign)
11:48am
6-K
1r0iex9idd3bpg6g
22 Jul 19
Current report (foreign)
11:35am
424B4
q8rarnx5
19 Jul 19
Prospectus supplement with pricing info
12:00am
F-6EF
5vhnf7su cxl9r1d16
18 Jul 19
Automatic registration for ADRs (foreign)
9:30am
EFFECT
jnphhbpzbw7l3g7
18 Jul 19
Notice of effectiveness
12:15am
F-1MEF
4e4g9 9hlxq
17 Jul 19
Registration statement to add securities to prior F-1 registration
7:55pm
S-8
icbc grrpv9yi6hrfmu
17 Jul 19
Registration of securities for employees
5:24pm
FWP
qor9yz
16 Jul 19
Free writing prospectus
8:54am
F-1/A
yuemmry3f7w46t
16 Jul 19
Registration statement (foreign) (amended)
8:05am
F-6 POS
uaf65 r0nqdh
15 Jul 19
Automatic registration for ADRs (post-effective amendment, foreign)
5:01pm
CERT
c63shkhzap3ud57c
15 Jul 19
Certification of approval for exchange listing
2:37pm
8-A12B
34hdh4ox9kf25wn 92og
12 Jul 19
Registration of securities on exchange
4:52pm
FWP
ed1yap wg
12 Jul 19
Free writing prospectus
11:53am